Skip to main content
. 2019 Jan 1;10(1):211–222. doi: 10.7150/jca.26444

Table 2.

Logistic regression analysis for predicting TIMT4 according to clinicopathological characteristics

High PD-L1/High CD8+ TIL High PD-L1/High CD8+ TIL
OR P OR P
age >65y 1.32 (1.007-1.729) 0.044 1.172 (0.907-1.513) 0.224
gender female 1.45 (1.112-1.891) 0.006 1.549 (1.201-1.998) 0.001
histology SCC 0.838 (0.645-1.090) 0.188 0.897 (0.699-1.151) 0.391
smoking history smoker 0.809 (0.514-1.273) 0.35 0.846 (0.545-1.313) 0.455
EGFR mutant 0.52 (0.285-0.951) 0.031 0.45 (0.256-0.790) 0.005
KRAS mutant 1.045 (0.737-1.486) 0.801 1.094 (0.780-1.528) 0.596
T stage T3-4 0.883 (0.609-1.282) 0.514 0.815 (0.572-1.160) 0.256
N stage N1-2 0.996 (0.748-1.326) 0.98 0.93 (0.708-1.220) 0.599
M stage M1-2 0.522 (0.211-1.291) 0.159 0.466 (0.206-1.057) 0.068
TMB >median 1.191 (0.911-1.558) 0.202 1.122 (0.869-1.447) 0.377
IFNγ expression >median 13.581 (9.542-19.33) <0.001 13.296 (9.752-18.128) <0.001

OR, odds ratio; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; SCC, squamous cell carcinoma; EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene.